

A close-up photograph of a female scientist in a white lab coat, wearing safety glasses and a white face mask. She is focused on her work, using a pipette to transfer liquid into a small vial. The background is a blurred laboratory setting. The entire image has a warm, orange-red color cast.

# Spain for **Life Sciences**

**INVESTIN**  
**SPAIN**



# Why Spain for *Life Sciences?*

- ✓ Solid basic science.
- ✓ Integrated healthcare system.
- ✓ Consolidation of biotechnology sector and an established pharmaceutical industry.
- ✓ Excellent infrastructure for innovation.
- ✓ Government support.
- ✓ Highly qualified workforce.



## Facts & Figures



### An integrated and protective healthcare system

800 hospitals (40% public and 60% private) and 300,000 professionals.

**Public healthcare** represents **6.3%** of Spain's GDP and **private healthcare** represents **2.7%** of Spain's GDP.

Substantial collaboration between public and private sector.



### Pharmaceutical industry leads R&D spending in Spain

The sector accounts for **20% of all private R&D spending** in Spain.

€1.21 billion in R&D.

12% of all R&D employment in Spanish industry.



### Top country in Europe in clinical testing

Spain collaborates in nearly **20%** of international clinical trials.

**1,000 clinical trials** performed at Spanish hospitals.

Clinical trials represent 45% of pharma investment in Spain.



### Healthcare technology market, a key player in exports

**1,000 companies** and an €8 billion turnover.

Exports worth **€3.5 billion** Europe takes 54% of exports.



### Participation in the international scientific arena

**12<sup>th</sup> scientific power in the world** and 5<sup>th</sup> in terms of scientific production in the EU15.



### A good standing in the EU pharma industry

5<sup>th</sup> in sales, 5<sup>th</sup> in job creation, 6<sup>th</sup> in pharma production.

**425 pharma companies** established in Spain, 60% of them are foreign.

Pharma exports represent 23% of the total in high technology products in Spain.



### Favourable legal framework for R&D activities

Company tax rate deductions of up to **42% for R&D** investment and up to 12% for innovation.

**40% deduction** in social security contributions for R&D workers.



### Private investment is increasingly interested in Life Sciences

**14.3% accounted** for by Life Sciences companies.

The **Healthcare sector ranks 2<sup>nd</sup>** and the **Biotech sector ranks 5<sup>th</sup>** in the number of venture capital transactions.



### Growing number of biotech companies

**2,800 companies** involved in biotech activities and more than 751 strictly companies.

**105,000 employees**, 10,000 activities exclusively dedicated to R&D.

## OUR SERVICES



Advice on business **start-ups**



**Locations** search



**Focal point** between central and regional authorities



Tailored industry **know-how**



Identifying **business opportunities**



Organising **agendas**



**Immigration** advice



Identifying **strategic partners** and technology partners



**Institutional** support



**Funding** and incentives **search**



Connectivity with **investors**



**After-care** service

## OUR INTERNATIONAL NETWORK



**Head office:**  
Paseo de la Castellana 278  
28046 Madrid (Spain)  
investinspain@icex.es  
[www.investinspain.org](http://www.investinspain.org)



NIPO 114210412



**ICEX**

**INVESTIN  
SPAIN**